Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

BRISBANE, Calif., Feb. 17 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the fourth quarter and 12 months ended December 31, 2009.  InterMune also highlighted its recent clinical development and business activities, and previewed upcoming milestones in 2010.  

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Fourth quarter and recent events have been highlighted by the very important developments related to the regulatory progress of pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis, or IPF.  Our New Drug Application (NDA) for pirfenidone was granted Priority Review status on January 4, and is scheduled to be discussed at an FDA advisory committee meeting on March 9, 2010.  If approved by the FDA, pirfenidone would be the first approved medicine for the approximately 100,000 Americans who suffer from this terrible disease.  Regarding Europe, we currently expect to submit a Marketing Authorization Application (MAA) for pirfenidone in the European Union in the current quarter."  

Mr. Welch continued, "We were pleased to report in January promising top-line results of the multiple-ascending-dose study of ritonavir-boosted RG7227 (ITMN-191) with standard of care, and look forward to providing further data on RG7227 during the year."

Clinical Development, Business Highlights and Upcoming Milestones

Pirfenidone:  

  • On January 4, we announced the NDA for pirfenidone had been ac
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... /PRNewswire-iReach/ -- Today leading web researchers Change Sciences Group ... web sites for usability, engagement, and conversion. The rankings ... which compares how people experience sites with competitors and ... The top three performers are easier to use, more ... performers have usability problems, lack aspects of design that ...
(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...
(Date:6/18/2013)... Quebec , June 18, 2013 Valeant ... TSX: VRX) (the "Company") announced today that VPII Escrow ... the Company, has launched its offer of approximately $3.2 ... "Notes").  The Notes will be due in 2021 and ... The Company intends to use the net proceeds ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... 2011 When consumers are offered a cost-neutral choice ... store or through a mail-order pharmacy, they split their ... study from CVS Caremark (NYSE: CVS ) ... study, published in the January edition of the ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced ... BMN 701, a novel fusion protein of insulin-like growth factor ... treatment of Pompe disease. "We have a strong ... medical needs and expect to leverage our clinical and regulatory ...
Cached Medicine Technology:CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions 2CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions 3BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease 2BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease 3
(Date:6/19/2013)... Children had half as many emergency department visits if ... five or more days a week, according to new ... Hospital and Johns Hopkins University. , The new study ... of Pediatrics and will be presented at the ... important step in understanding where primary care practices and ...
(Date:6/19/2013)... are increasingly common on college campuses, but are ... up"? A new study by researchers with The ... published online by the Archives of Sexual ... behaviors associated with sexual hookups, particularly among first-year ... negative emotional and physical health outcomes as a ...
(Date:6/19/2013)... block the body,s system for repairing damage to the ... unlikely as it may seem, those compounds are sparking ... driven by a mutation in BRCA, a gene that ... the mutation. The compounds, termed PARP inhibitors, are the ... of Chemical & Engineering News . C&EN is ...
(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...
(Date:6/19/2013)... Alternatives, a revolutionary new treatment facility located ... drugs while allowing them to continue drinking alcohol. Drs. ... believe that abstinence-only approaches force people to wait until ... this approach hurts instead of helping. It is ... need treatment for addiction but only 3 million seek ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3
... way to treat castrate resistant cells in prostate cancer ... For more than 60 years the main way ... the hormones that fuel growth of the cancer cells. ... the tumour growth resumes, the disease in incurable. The ...
... , ... ... ... ...
... ... ... ... ...
... ... ... of complex government regulation some of the stand-out questions include:, , ,   ... How are these standards impacted by the convergence of media and conflation of traditional media ...
... ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Effective prostate cancer treatment discovery 2Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 2Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 3Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 4Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 2Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 3Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 4Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 5Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 6Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 7Health News:Alan Chapell, President of Chapell & Associates to Deliver Keynote at the Next AdMonsters US Leadership Forum 2Health News:Alan Chapell, President of Chapell & Associates to Deliver Keynote at the Next AdMonsters US Leadership Forum 3Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 2Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 3Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 4Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 5Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 6Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 7Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 8Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 2Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 3Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 4Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 5Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 6
... Blood Collection Tubes are used ... blood samples for use with ... chemistry cartridges requiring either 95 ... sample. These tubes are Mylar-wrapped ...
... FEMTO LDV, the first compact, mobile femtosecond ... a versatile, powerful platform for a wide ... basic system addresses the demand of refractive ... is consistent with an efficient LASIK work-flow. ...
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
Medicine Products: